Viewing Study NCT06538012

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-26 @ 11:08 AM
Ignite Modification Date: 2026-05-16 @ 3:19 PM
Study NCT ID: NCT06538012
Status: RECRUITING
Last Update Posted: 2024-10-15
First Post: 2024-07-31
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
Sponsor: Essen Biotech
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Lung Cancer View
None Lung Cancer Metastatic View
None Lung Cancer, Non-small Cell View
None Lung Cancer Recurrent View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Tumor Infiltrating Lymphocytes View
None CAR-T CELL View
None Biological Therapy View
None Advanced or Metastatic Refractory View
None Immunotherapy View
None TIL View